TSHA as reported
Taysha Gene Therapies, Inc. reported $7.5M of revenue over the trailing twelve months, +3.4% on the year before. 9 reported series are charted on this page, each one as filed.
$7.5M
Revenue, trailing twelve months · to Q1 2026 · +3.4% against the twelve months before
- Net Income
- −$130M
Net Income · +50% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$112M
Free Cash Flow · +34% year on year · trailing twelve months to Q1 2026
- Op Margin
- −1178%
Op Margin · trailing twelve months to Q2 2025
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $7.5M | +3.4% | Q1 2026 |
| Net Income | −$130M | +50% | Q1 2026 |
| EPS | −$0.38 | +12% | Q1 2026 |
| Op Margin | −1178% | n/a | Q2 2025 |
| Net Margin | −1161% | n/a | Q2 2025 |
| ROE | −47% | n/a | Q1 2026 |
| ROA | −34% | n/a | Q1 2026 |
| ROIC | 417% | n/a | Q1 2026 |
| Free Cash Flow | −$112M | +34% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Taysha Gene Therapies, Inc. (TSHA) - Revenue & ProfitRevenue & ProfitTaysha Gene Therapies, Inc. (TSHA)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com